• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of cmajCMAJ Information for AuthorsCMAJ Home Page
CMAJ. Mar 15, 1993; 148(6): 913–917.
PMCID: PMC1490730

Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem.

Abstract

The guidelines proposed by Laupacis and associates do not stem from economic theory and are a prescription for uncontrolled growth in health care expenditure. In particular, cost-effectiveness ratios provide information relevant to allocation decisions only in very special circumstances that do not usually apply in practice. When two interventions are compared a positive cost-effectiveness ratio (the common case) can tell us, at best, what additional costs will be incurred to generate the additional outcomes. From an economic perspective the information required to determine the attractiveness of a new technology is different: the source of the additional resource requirements must be identified and the opportunity cost of their redeployment estimated. Because the cost-effectiveness ratio (cost/-QALY) is sensitive to the method chosen to calculate QALYs, guidelines that do not specify (or justify) the appropriate method for calculating outcomes are unlikely to produce comparable results (or common yardsticks). In a health care system such as Canada's in which there is always pressure to introduce more effective technology, even if it is more costly, there is a risk of using such noncomparable data to justify adoption of particular technologies. The method of technology evaluation proposed by us is consistent with the stated goal of maximizing the community's health-related well-being for a given level of resources allocated to health care and ensures that new technologies are adopted only if this adoption represents an improvement in resource allocation.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (991K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977 Mar 31;296(13):716–721. [PubMed]
  • Birch S, Gafni A. Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be? J Health Econ. 1992 Oct;11(3):279–296. [PubMed]
  • Birch S, Donaldson C. Applications of cost-benefit analysis to health care. Departures from welfare economic theory. J Health Econ. 1987 Sep;6(3):211–225. [PubMed]
  • Loomes G, McKenzie L. The use of QALYs in health care decision making. Soc Sci Med. 1989;28(4):299–308. [PubMed]
  • Mehrez A, Gafni A. Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decis Making. 1989 Apr-Jun;9(2):142–149. [PubMed]
  • Read JL, Quinn RJ, Berwick DM, Fineberg HV, Weinstein MC. Preferences for health outcomes. Comparison of assessment methods. Med Decis Making. 1984;4(3):315–329. [PubMed]
  • Mehrez A, Gafni A. Evaluating health related quality of life: an indifference curve interpretation for the time trade-off technique. Soc Sci Med. 1990;31(11):1281–1283. [PubMed]
  • Hornberger JC, Redelmeier DA, Petersen J. Variability among methods to assess patients' well-being and consequent effect on a cost-effectiveness analysis. J Clin Epidemiol. 1992 May;45(5):505–512. [PubMed]
  • Gafni A, Zylak CJ. Ionic versus nonionic contrast media: a burden or a bargain? CMAJ. 1990 Sep 15;143(6):475–478. [PMC free article] [PubMed]
  • Gafni A. Measuring the adverse effects of unnecessary hypertension drug therapy: QALYs vs HYE. Clin Invest Med. 1991 Jun;14(3):266–270. [PubMed]
  • Wagstaff A. QALYs and the equity-efficiency trade-off. J Health Econ. 1991 May;10(1):21–41. [PubMed]
  • Ben-Zion U, Gafni A. Evaluation of public investment in health care. Is the risk irrelevant? J Health Econ. 1983 Aug;2(2):161–165. [PubMed]
  • Mehrez A, Gafni A. The healthy-years equivalents: how to measure them using the standard gamble approach. Med Decis Making. 1991 Apr-Jun;11(2):140–146. [PubMed]
  • Gafni A. Willingness-to-pay as a measure of benefits. Relevant questions in the context of public decisionmaking about health care programs. Med Care. 1991 Dec;29(12):1246–1252. [PubMed]
  • Johannesson M, Johansson PO, Jönsson B. Economic evaluation of drug therapy: a review of the contingent valuation method. Pharmacoeconomics. 1992 May;1(5):325–337. [PubMed]
  • Gafni A, Birch S. Equity considerations in utility-based measures of health outcomes in economic appraisals: an adjustment algorithm. J Health Econ. 1991 Oct;10(3):329–342. [PubMed]

Articles from CMAJ : Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...